✦ LIBER ✦

PCV51 IRBESARTAN IS COST-SAVING COMPARED TO AMLODIPINE AND STANDARD BLOOD PRESSURE TREATMENT IN PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION AND NEPHROPATHY IN HUNGARY

✍ Scribed by AJ Palmer; K Borsos; S Roze; L Annemans; M Lamotte; R Rodby; WJ Valentine

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CS3 IRBESARTAN IS PROJECTED TO BE COST A

✍ AJ Palmer; S Roze; Valentine Wj; L Annemans; S Gabriel; R Chen 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

An Asian Regional Analysis of Cost-Effec

✍ Lieven Annemans; Nadia Demarteau; Shanlian Hu; Tae-Jin Lee; Zaher Morad; Thanom 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 396 KB

Irbesartan is projected to be cost and l

✍ Palmer, Andrew J.; Annemans, Lieven; Roze, Stephane; Lapuerta, Pablo; Chen, Rola 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 66 KB

CV4 IRBESARTAN IS PROJECTED TO BE COST A

✍ AJ Palmer; L Annemans; S Roze; M Lamotte; P Lapuerta; S Gabriel; R Chen; P Carit 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

Health economic implications of irbesart

✍ Andrew J. Palmer; William J. Valentine; Joshua A. Ray; Stephane Roze; Noemi Musz 📂 Article 📅 2007 🏛 Springer 🌐 French ⚖ 212 KB

PCV72 COST-EFFECTIVENESS ANALYSIS OF ADD

✍ P Kutscherauer; R Kodym; D Bartaskova 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB